A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP)

被引：0
|
作者：
Perdon, Karen Mae [1 ]
Kim, Dae Won [1 ]
Balmes, Gener C. [1 ]
VanAnh Trinh [1 ]
McIntyre, Susan E. [1 ]
Diab, Adi [1 ]
Amaria, Rodabe Navroze [1 ]
Patel, Sapna Pradyuman [1 ]
Hwu, Patrick [1 ]
James, Marihella [1 ]
Philip, Ann [1 ]
Vardeleon, Anna [1 ]
Cain, Suzanne [1 ]
Hwu, Wen-Jen [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20088
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab expanded access program (EAP) in Spain: clinical activity.
    Arance, Ana
    Piulats, Josep M.
    Rodas, Ivan Marquez
    Manzano, Jose Luis
    Berrocal, Alfonso
    Algarra, Salvador Martin
    Crespo, Guillermo
    Rodriguez, Delvys
    Guerrero, Miguel Angel Berciano
    Soria, Ainara
    Ruiz, Elisabeth Perez
    Castano, Almudena Garcia
    Montagut, Clara
    Puertolas, Teresa
    Aguado, Carlos
    Royo, Maria Angeles
    Blanco, Remei
    Munoz-Couselo, Eva
    Sanchis, Pilar Mut
    Gonzalez-Cao, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    Gonzalez-Cao, M.
    Arance, A.
    Piulats, J. M.
    Marquez-Rodas, I.
    Manzano, J. L.
    Berrocal, A.
    Crespo, G.
    Rodriguez, D.
    Perez-Ruiz, E.
    Berciano, M.
    Soria, A.
    Castano, A. G.
    Espinosa, E.
    Montagut, C.
    Alonso, L.
    Puertolas, T.
    Aguado, C.
    Royo, M. A.
    Blanco, R.
    Rodriguez, J. F.
    Munoz, E.
    Mut, P.
    Barron, F.
    Martin-Algarra, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 761 - 768
  • [3] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    M. González-Cao
    A. Arance
    J. M. Piulats
    I. Marquez-Rodas
    J. L. Manzano
    A. Berrocal
    G. Crespo
    D. Rodriguez
    E. Perez-Ruiz
    M. Berciano
    A. Soria
    A. G. Castano
    E. Espinosa
    C. Montagut
    L. Alonso
    T. Puertolas
    C. Aguado
    M. A. Royo
    R. Blanco
    J. F. Rodríguez
    E. Muñoz
    P. Mut
    F. Barron
    S. Martin-Algarra
    Clinical and Translational Oncology, 2017, 19 : 761 - 768
  • [4] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience
    Margolin, Kim Allyson
    Hamid, Omid
    Weber, Jeffrey S.
    Pavlick, Anna C.
    Hodi, F. Stephen
    Amin, Asim
    Bennett, Kelly
    Michener, Tracy
    Minor, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] NUSINERSEN FOR SMA1: THE ITALIAN EXPANDED ACCESS PROGRAM (EAP) EXPERIENCE
    Albamonte, E.
    Pane, M.
    Messina, S.
    D'Amico
    Bertini, E.
    Bruno, C.
    Vita, G.
    Casiraghi, J.
    Binetti, L.
    Mercuri, E.
    Sansone, V. A.
    MUSCLE & NERVE, 2017, 56 : S2 - S3
  • [7] SINGLE-INSTITUTION EXPERIENCE WITH APRV
    Kommareddy-Sloane, Siri
    Madsen, Erik
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 288 - 288
  • [8] The use of nusinersen in the "real world": the UK and Ireland experience with the expanded access program (EAP)
    Scoto, M.
    Manzue, A.
    Main, M.
    Munot, P.
    Tillmann, R.
    Bettolo, C. Marini
    Mayhew, A.
    Muni-Lofra, R.
    White, K.
    Baxter, P.
    Tirupathi, S.
    Douglas, I.
    Douglas, M.
    Macauley, S.
    Childs, A-M
    O'Rourke, D.
    Hartley, L.
    Hughes, I.
    McCullagh, G.
    Spinty, S.
    Madhu, R.
    Gregson, S.
    Gowda, V.
    Wraige, E.
    Horrocks, I.
    Brunklaus, A.
    Di Marco, M.
    Dunne, J.
    Brown, S.
    Mochrie, R.
    Illingworth, M.
    Krishnakumar, D.
    Kirkpatrick, M.
    Ramdas, S.
    Vijayakumar, K.
    Selby, V.
    Kulshrestha, R.
    Willis, T.
    Straub, V.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S25 - S25
  • [9] Expanded access program (EAP) to investigational drugs.
    Talarico, L
    Pazdur, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 519S - 519S
  • [10] Pemetrexed with or without a platinum compound in patients with malignant mesothelioma: A single institution "Expanded Access Program" experience
    Baas, P
    Burgers, S
    Lieverst, J
    Dalesio, O
    van Zandwijk, N
    LUNG CANCER, 2005, 49 : S219 - S219
12345